B. Riley analyst Mayank Mamtani raised the firm’s price target on Journey Medical (DERM) to $12 from $9 and keeps a Buy rating on the shares following a transfer of coverage. The firm expects increased visibility into Emrosi’s early launch performance with the Q2 results in mid-August.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: